Crinetics Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Crinetics Pharmaceuticalshan disminuido a un ritmo medio anual de -37.3%, mientras que en la industria Biotechs los ingresos han sido de growing a 17.4% anuales. Los ingresos han sido growing a una tasa media anual de 31%.
Key information
-36.0%
Earnings growth rate
-13.7%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 33.6% |
Return on equity | -39.8% |
Net Margin | -5,345.9% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress
Apr 24Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Jan 19Crinetics Pharmaceuticals appoints Garlan Adams as general counsel
Jun 16Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
May 13Crinetics Pharmaceuticals EPS misses by $0.04
May 06Have Insiders Been Selling Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares?
Mar 21Companies Like Crinetics Pharmaceuticals (NASDAQ:CRNX) Are In A Position To Invest In Growth
Jan 27Insider Buying: The Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Founder Just Bought US$65k Worth Of Shares
Dec 06Revenue & Expenses BreakdownBeta
How Crinetics Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 4 | -215 | 58 | 169 |
30 Sep 23 | 5 | -199 | 52 | 0 |
30 Jun 23 | 5 | -184 | 49 | 0 |
31 Mar 23 | 4 | -175 | 46 | 0 |
31 Dec 22 | 5 | -164 | 42 | 130 |
30 Sep 22 | 5 | -150 | 38 | 0 |
30 Jun 22 | 5 | -136 | 33 | 0 |
31 Mar 22 | 4 | -119 | 28 | 0 |
31 Dec 21 | 1 | -108 | 25 | 84 |
30 Sep 21 | 0 | -98 | 22 | 0 |
30 Jun 21 | 0 | -89 | 21 | 0 |
31 Mar 21 | 0 | -79 | 19 | 0 |
31 Dec 20 | 0 | -74 | 18 | 0 |
30 Sep 20 | 0 | -67 | 16 | 0 |
30 Jun 20 | 1 | -63 | 16 | 0 |
31 Mar 20 | 1 | -59 | 14 | 0 |
31 Dec 19 | 1 | -50 | 14 | 0 |
30 Sep 19 | 2 | -44 | 13 | 0 |
30 Jun 19 | 2 | -38 | 11 | 0 |
31 Mar 19 | 2 | -31 | 9 | 0 |
31 Dec 18 | 2 | -27 | 7 | 0 |
30 Sep 18 | 2 | -21 | 5 | 0 |
30 Jun 18 | 2 | -16 | 3 | 0 |
31 Mar 18 | 2 | -12 | 3 | 0 |
31 Dec 17 | 2 | -9 | 2 | 0 |
31 Dec 16 | 1 | -6 | 2 | 0 |
Beneficios de calidad: CRNX actualmente no es rentable.
Creciente margen de beneficios: CRNX actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: CRNX no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 37.3% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de CRNX en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: CRNX no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Biotechs (-42.7%).
Return on Equity
Alto ROE: CRNX tiene un Rendimiento de los fondos propios negativo (-36.41%), ya que actualmente no es rentable.